Gene therapy or immunotherapy: which approach is more likely to deliver a cure for HIV?
Ibalizumab monoclonal antibody is effective in real-world use
First trial results of new immune-modulating drugs presented in Mexico City
Monoclonal antibody may lead to long-term viral load reduction
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows
The Miami monkey cured with two antibodies
Dual-antibody combination therapy produces three to seven months of viral suppression without pills
Ibalizumab, active against highly resistant HIV, now approved in US
Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys
